Here are the DEF 14A proxy statements from Theravance Biopharma, Inc. (TBPH) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TBPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TBPH filings page.
Theravance Biopharma, Inc. is asking shareholders to vote at its 2026 Annual General Meeting on June 12, 2026 in Dublin, Ireland. Shareholders will elect six directors to one‑year terms, ratify Ernst & Young LLP as independent auditor for 2026, and approve a non‑binding advisory vote on executive pay.
The board is being reduced from nine to six members and fully declassified, so all directors stand for annual election. The company highlights pay-for-performance features in 2025 executive compensation and details strong governance practices, independent board leadership, and active board committees overseeing strategy, risk, and capital allocation.